Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Devilish Details: Icahn Looks To Boost Bristol/ImClone Offer

Executive Summary

Pity Carl Icahn. The biotech industry's best-known activist shareholder and chairman of ImClone saw the value of his holdings plummet following the Food and Drug Administration's 2001 rejection of the company's lead cancer drug, the EGFR inhibitor Erbitux (cetuximab), and the succeeding insider-trading scandal that sent CEO Sam Waksal to jail

You may also be interested in...



With Proxy Fight Averted, Genzyme Can Review Damage Done By A Year Of Manufacturing Troubles

Now that Genzyme has avoided a proxy fight with Carl Icahn and associates, the biotech's next step likely will be to consider the damage left by a year's worth of manufacturing woes and the problems that resulted, including shortages of its top-selling products, the launch of new competition to those drugs, and an FDA consent decree governing operations at its Allston Landing, Mass., plant

With Proxy Fight Averted, Genzyme Can Review Damage Done By A Year Of Manufacturing Troubles

Now that Genzyme has avoided a proxy fight with Carl Icahn and associates, the biotech's next step likely will be to consider the damage left by a year's worth of manufacturing woes and the problems that resulted, including shortages of its top-selling products, the launch of new competition to those drugs, and an FDA consent decree governing operations at its Allston Landing, Mass., plant

Lilly’s ImClone Buy Adds Oncology Candidates And Pipeline Pressures

Eli Lilly announced Oct. 6 that it is acquiring ImClone for $6.5 billion, confirming rumors that had been circulating since the middle of the previous week. The central question now is whether Lilly can turn the buyout into a win for shareholders

Related Content

UsernamePublicRestriction

Register

ID1132679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel